Pediatric Oncology Department, Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan.
Research Department, Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan.
Leuk Lymphoma. 2020 Dec;61(14):3369-3377. doi: 10.1080/10428194.2020.1817434. Epub 2020 Sep 13.
This study aimed to determine response rates, overall survival (OS), event-free survival (EFS) and toxicity profile of an outpatient chemotherapy regimen based on gemcitabine and vinorelbine (GV) for relapsed childhood Hodgkin lymphoma (HL). This was a retrospective study that included 41 patients up to the age of 18 years with relapsed HL. Twelve patients (29%) had primary progressive disease (PPD), 6 (15%) had early relapse (ER) and 23 (56%) had late relapse (LR). The overall initial response rate was 83% (LR: 87%, ER: 83%, PPD: 75%. -value: .2). Three-year combined OS was 80% (LR: 89%, ER: 80%, PPD: 65%. -value: .07) and EFS 71% (LR: 86%, ER: 62%, PPD: 47%. -value: .01). There were no toxic deaths. Febrile neutropenia was observed in four patients (9.6%) and lung toxicity in 1 patient (2.4%). This study suggests that outpatient GV is an effective and low toxicity salvage regimen for relapsed childhood HL.
本研究旨在确定吉西他滨联合长春瑞滨（GV）方案作为复发儿童霍奇金淋巴瘤（HL）的门诊化疗方案的缓解率、总生存（OS）、无事件生存（EFS）和毒性特征。这是一项回顾性研究，共纳入 41 例年龄在 18 岁以下的复发 HL 患者。12 例（29%）为原发性进展性疾病（PPD），6 例（15%）为早期复发（ER），23 例（56%）为晚期复发（LR）。总体初始缓解率为 83%（LR：87%，ER：83%，PPD：75%。-值：0.2）。3 年总 OS 为 80%（LR：89%，ER：80%，PPD：65%。-值：0.07），EFS 为 71%（LR：86%，ER：62%，PPD：47%。-值：0.01）。无治疗相关性死亡。4 例（9.6%）出现发热性中性粒细胞减少症，1 例（2.4%）出现肺毒性。本研究表明，门诊 GV 是一种有效且毒性低的复发儿童 HL 挽救治疗方案。
